Michael Wang, MD, discusses the evolution of treatment in mantle cell lymphoma.
Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses the evolution of treatment in mantle cell lymphoma (MCL).
The field of MCL has migrated from chemotherapy to chemotherapy-free targeted therapies, says Wang. Now is the era of immunotherapies and cell therapies, adds Wang. Astherapies continue to be developed and perfected, more novel therapies will emerge and the field will shift into a targeted therapies era, says Wang.
Investigators are learning how to rationally combine these therapy options, either concurrently or sequentially. Instead of relying on any single modality to increase efficacy or cure, agents are being combined in a rational, scientific way to yield the best results possible, concludes Wang.